{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T02:27:57Z","timestamp":1793672877314,"version":"4.5.1"},"reference-count":29,"publisher":"Academy of Medicine, Singapore","issue":"10","license":[{"start":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:00:00Z","timestamp":1790640000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Acad Med Singap"],"abstract":"<jats:p>Introduction: Neurofibromatosis type 1 (NF1) is a multisystem genetic disorder with wide phenotypic variability, necessitating coordinated multidisciplinary care and Singapore-relevant guidance. This study aimed to develop Singapore-specific, consensus-based recommendations for NF1 diagnosis, surveillance, and management. \nMethods: The study involved 2 rounds of online surveys and a participant meeting with 24 experts from Singapore. Following a literature review, a 151-statement questionnaire was developed (133 Likert-style statements, 13 open-ended questions, 5 single-select questions). Statements were rated on a 9-point Likert scale with a predefined consensus threshold of \u226575%; analyses were performed after each round.\nResults: Surveys 1 and 2 involved 19 and 17 participants, respectively, with 14 attending the meeting. Consensus was reached for 113\/133 statements in Survey 1 and 9\/21 in Survey 2. Experts reached consensus on genetic testing across diagnostic scenarios, including Sprouty\u2011related EVH1 domain\u2011containing protein 1 analysis and ribonucleic acid testing. Agreed surveillance incorporated examinations twice a year until the age of 5 years, at least annually thereafter in childhood, annual symptom checks in adults with triennial specialist review, and targeted MRI-based imaging, including whole-body magnetic resonance imaging around transition. Management recommendations favoured multidisciplinary review and surgical resection when feasible.\nConclusion: This Delphi consensus provides unified recommendations to support consistent NF1 care across paediatric and adult services in Singapore, while highlighting areas without consensus and priorities for implementation and further research.<\/jats:p>","DOI":"10.47102\/annals-acadmedsg.2026152","type":"journal-article","created":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T01:33:38Z","timestamp":1790732018000},"page":"528","source":"Crossref","is-referenced-by-count":1,"title":["Recommendations for the diagnosis and management of neurofibromatosis type 1 in Singapore: A Delphi consensus"],"prefix":"10.47102","volume":"55","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7589-1632","authenticated-orcid":false,"given":"Nikki","family":"Fong","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/0228w5t68","id-type":"ROR","asserted-by":"publisher"}],"name":"KK Women's and Children's Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ee Shien","family":"Tan","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/0228w5t68","id-type":"ROR","asserted-by":"publisher"}],"name":"KK Women's and Children's Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1558-3627","authenticated-orcid":false,"given":"Joanne","family":"Ngeow","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03bqk3e80","id-type":"ROR","asserted-by":"publisher"}],"name":"National Cancer Centre Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0046-3518","authenticated-orcid":false,"given":"Jeanette","family":"Yuen","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03bqk3e80","id-type":"ROR","asserted-by":"publisher"}],"name":"National Cancer Centre Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3109-2839","authenticated-orcid":false,"given":"Jianbang","family":"Chang","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03bqk3e80","id-type":"ROR","asserted-by":"publisher"}],"name":"National Cancer Centre Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"26165","published-online":{"date-parts":[[2026,9,29]]},"reference":[{"key":"ref0","doi-asserted-by":"crossref","unstructured":"1. Hirbe AC, Gutmann DH. Neurofibromatosis type 1: a multidisciplinary approach to care. Lancet Neurol 2014;13:834-43. DOI: 10.1016\/S1474-4422(14)70063-8","DOI":"10.1016\/S1474-4422(14)70063-8"},{"key":"ref1","unstructured":"2. Karaconji T, Whist E, Jamieson RV, et al. Neurofibromatosis Type 1: Review and Update on Emerging Therapies. Asia Pac J Ophthalmol (Phila) 2019;8:62-72."},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"3. Lee T-SJ, Chopra M, Kim RH, et al. Incidence and prevalence of neurofibromatosis type 1 and 2: a systematic review and meta-analysis. Orphanet J Rare Dis 2023;18:292. DOI: 10.1186\/s13023-023-02911-2","DOI":"10.1186\/s13023-023-02911-2"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"4. Legius E, Messiaen L, Wolkenstein P, et al. Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation. Genet Med 2021;23:1506-13. DOI: 10.1038\/s41436-021-01170-5","DOI":"10.1038\/s41436-021-01170-5"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"5. Fisher MJ, Blakeley JO, Weiss BD, et al. Management of neurofibromatosis type 1-associated plexiform neurofibromas. Neuro Oncol 2022;24:1827-44. DOI: 10.1093\/neuonc\/noac146","DOI":"10.1093\/neuonc\/noac146"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"6. Yu Y, Wei C, Yue M, et al. From benign neurofibromas to malignant peripheral nerve sheath tumors (MPNST): a gaming among multiple factors. Cell Oncol (Dordr) 2025;48:841-57. DOI: 10.1007\/s13402-025-01054-9","DOI":"10.1007\/s13402-025-01054-9"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"7. Carton C, Evans DG, Blanco I, et al. ERN GENTURIS tumour surveillance guidelines for individuals with neurofibromatosis type 1. eClinicalMedicine 2023;56:101818. DOI: 10.1016\/j.eclinm.2022.101818","DOI":"10.1016\/j.eclinm.2022.101818"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"8. Gutmann DH, Ferner RE, Listernick RH, et al. Neurofibromatosis type 1. Nat Rev Dis Primers 2017;3:17004. DOI: 10.1038\/nrdp.2017.4","DOI":"10.1038\/nrdp.2017.4"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"9. Landry JP, Schertz KL, Chiang YJ, et al. Comparison of Cancer Prevalence in Patients With Neurofibromatosis Type 1 at an Academic Cancer Center vs in the General Population From 1985 to 2020. JAMA Netw Open 2021;4:e210945. DOI: 10.1001\/jamanetworkopen.2021.0945","DOI":"10.1001\/jamanetworkopen.2021.0945"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"10. Nishida Y, Ikuta K, Natsume A, et al. Establishment of in-hospital clinical network for patients with neurofibromatosis type 1 in Nagoya University Hospital. Sci Rep 2021;11:11933. DOI: 10.1038\/s41598-021-91345-6","DOI":"10.1038\/s41598-021-91345-6"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"11. Uusitalo E, Rantanen M, Kallionp\u00e4\u00e4 RA, et al. Distinctive Cancer Associations in Patients With Neurofibromatosis Type 1. J Clin Oncol 2016;34:1978-86. DOI: 10.1200\/JCO.2015.65.3576","DOI":"10.1200\/JCO.2015.65.3576"},{"key":"ref11","unstructured":"12. National Multi-Center Treatment Collaboration Group For Neurofibromatosis Type, National Multi-Center Research Platform For Plastic And Reconstructive Surgery. Expert consensus on diagnosis and management of neurofibromatosis type 1 (2021 Edition). Chin J Reparative Reconstr Surg 2021;35:1384-95."},{"key":"ref12","unstructured":"13. Group of Neurofibromatosis, Plastic and Reconstructive Surgery Society of Chinese Medical Association, China Rare Disease Alliance Neurofibromatosis Expert Committee. Interpretation of the Expert Consensus for Full Course Management of Plexiform Neurofibroma (2025 Edition). Chin J Reparative Reconstr Surg 2026;40:519-25."},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"14. Rana S, Low CE, Karthikeyan M, et al. A Systematic Review of Diagnostic Modalities and Strategies for the Assessment of Complications in Adult Patients with Neurofibromatosis Type 1. Cancers (Basel) 2024;16:1119. DOI: 10.3390\/cancers16061119","DOI":"10.3390\/cancers16061119"},{"key":"ref14","unstructured":"15. Friedman JM. Neurofibromatosis 1. In: Adam MP, Bick S, Mirzaa GM, et al. (Eds). GeneReviews\u00ae [Internet]. Seattle: University of Washington; 1993."},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"16. Yap Y-S, Wong J, Chan M, et al. Abstract P3-08-09: Clinical and Pathological Characteristics of Breast Cancer in Women with Neurofibromatosis Type 1. Cancer Res 2012;72:Abstract nr P3-08-09. DOI: 10.1158\/0008-5472.SABCS12-P3-08-09","DOI":"10.1158\/0008-5472.SABCS12-P3-08-09"},{"key":"ref16","unstructured":"17. National Cancer Centre Singapore. Cancer Statistics. https:\/\/www.nccs.com.sg\/content\/singhealth-web\/nccs\/en\/your-care\/about-cancer\/cancer-statistics.html. Accessed 18 June 2026."},{"key":"ref17","unstructured":"18. Frontier Healthcare. Osteoporosis. https:\/\/frontierhealthcare.com.sg\/osteoporosis\/. Accessed 18 June 2026."},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"19. Tucker T, Schnabel C, Hartmann M, et al. Bone health and fracture rate in individuals with neurofibromatosis 1 (NF1). J Med Genet 2009;46:259-65. DOI: 10.1136\/jmg.2008.061895","DOI":"10.1136\/jmg.2008.061895"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"20. Gross AM, Plotkin SR, Watts NB, et al. Potential endpoints for assessment of bone health in persons with neurofibromatosis type 1. Clin Trials 2024;21:29-39. DOI: 10.1177\/17407745231201338","DOI":"10.1177\/17407745231201338"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"21. Chamseddin BH, Le LQ. Management of cutaneous neurofibroma: current therapy and future directions. Neurooncol Adv 2019;2:i107-16. DOI: 10.1093\/noajnl\/vdz034","DOI":"10.1093\/noajnl\/vdz034"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"22. Namgung H. Gastrointestinal stromal tumor with KIT mutation in neurofibromatosis type 1. J Korean Surg Soc 2011;81:276-80. DOI: 10.4174\/jkss.2011.81.4.276","DOI":"10.4174\/jkss.2011.81.4.276"},{"key":"ref22","unstructured":"23. Health Sciences Authority. Summary Report of Benefit-Risk Assessment - Selumetinib."},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"24. Chen AP, O\u2019Sullivan Coyne G, Wolters PL, et al. Efficacy and safety of selumetinib in adults with neurofibromatosis type 1 and symptomatic, inoperable plexiform neurofibromas (KOMET): a multicentre, international, randomised, placebo-controlled, parallel, double-blind, phase 3 study. Lancet 2025;405:2217-30. DOI: 10.1016\/S0140-6736(25)00986-9","DOI":"10.1016\/S0140-6736(25)00986-9"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"25. Gross AM, O\u2019Sullivan Coyne G, Dombi E, et al. Selumetinib in adults with NF1 and inoperable plexiform neurofibroma: a phase 2 trial. Nat Med 2025;31:105-15. DOI: 10.1038\/s41591-024-03361-4","DOI":"10.1038\/s41591-024-03361-4"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"26. Kim H, Yoon HM, Kim EK, et al. Safety and efficacy of selumetinib in pediatric and adult patients with neurofibromatosis type 1 and plexiform neurofibroma. Neuro Oncol 2024;26:2352-63. DOI: 10.1093\/neuonc\/noae121","DOI":"10.1093\/neuonc\/noae121"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"27. Wang Z, Zhang X, Li C, et al. Safety, pharmacokinetics and efficacy of selumetinib in Chinese adult and paediatric patients with neurofibromatosis type 1 and inoperable plexiform neurofibromas: The primary analysis of a phase 1 open\u2010label study. Clin Transl Med 2024;14:e1589. DOI: 10.1002\/ctm2.1589","DOI":"10.1002\/ctm2.1589"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"28. Widemann BC, Dombi E, Gillespie A, et al. Phase 2 randomized, flexible crossover, double-blinded, placebo-controlled trial of the farnesyltransferase inhibitor tipifarnib in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas. Neuro Oncol 2014;16:707-18. DOI: 10.1093\/neuonc\/nou004","DOI":"10.1093\/neuonc\/nou004"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"29. Weiss B, Widemann BC, Wolters P, et al. Sirolimus for non-progressive NF1-associated plexiform neurofibromas: an NF clinical trials consortium phase II study. Pediatr Blood Cancer 2014;61:982-6. DOI: 10.1002\/pbc.24873","DOI":"10.1002\/pbc.24873"}],"container-title":["Annals of the Academy of Medicine Singapore"],"original-title":[],"deposited":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T02:12:35Z","timestamp":1793671955000},"score":1,"resource":{"primary":{"URL":"https:\/\/annals.edu.sg\/nf1-clinical-recommendations-singapore\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,29]]},"references-count":29,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,10,30]]}},"URL":"https:\/\/doi.org\/10.47102\/annals-acadmedsg.2026152","relation":{},"ISSN":["2972-4066"],"issn-type":[{"value":"2972-4066","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,29]]}}}